Keeping Pace in Lung Cancer: Personalizing Treatment in NSCLC: Early-Stage Disease (Stage I-IIIa)

Keeping Pace in Lung Cancer
Personalizing Treatment in NSCLC: Early-Stage Disease (Stage I-IIIa)

ReachMD Healthcare Image

Personalizing treatment for patients with early-stage NSCLC has become more complex. Updated guidelines, the rapid pace of new data—are you prepared?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mark A. Socinski, MD
    Executive Medical Director
    AdventHealth Cancer Institute
    Orlando, FL 

    Consulting Fees: AstraZeneca, Genentech, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mirati Therapeutics, Inc., Novartis Pharmaceuticals, OncoC4, Inc., Spectrum Pharmaceuticals
    Research: Cullinan Oncology, Genentech, Mirati Therapeutics, Inc., OncoC4, Inc. Spectrum Pharmaceuticals 

    Patrick Forde, MBBCh
    Co-Director, Upper Aerodigestive Malignancies
    Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, MD 

    Consulting Fees: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Enable, F-star, G1 Therapeutics, Inc., Genentech, Gritstone, iTeos, Janssen, Merck, Novartis Pharmaceuticals
    Research: AstraZeneca, Bristol Myers Squibb, Novartis Pharmaceuticals, Regeneron

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Nick Lombardi has ownership interest in Vertex Pharmaceuticals.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Review evidence from clinical trials evaluating immuno-oncology therapies as adjuvant and neoadjuvant therapies for patients with early-stage non-small cell lung cancer
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pathologists, pulmonologists, oncology nurse practitioners, physician assistants, registered nurses, and pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 contact hours/0.025 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-23-007-H01-P. This learning activity is enduring-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ( 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from Bristol Myers Squibb and Merck & Co., Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free